Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
667 hedge funds and large institutions have $22B invested in Alexion Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 248 increasing their positions, 237 reducing their positions, and 66 closing their positions.
53% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 66
9% more capital invested
Capital invested by funds: $20.1B → $22B (+$1.83B)
3% more funds holding
Funds holding: 646 → 667 (+21)
5% more repeat investments, than reductions
Existing positions increased: 248 | Existing positions reduced: 237
0% more funds holding in top 10
Funds holding in top 10: 16 → 16 (0)
46% less call options, than puts
Call options by funds: $214M | Put options by funds: $394M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$103M |
| 2 |
Renaissance Technologies
New York
|
+$94.3M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$94M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$81.6M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$79.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$524M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$200M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$166M |
| 4 |
SSM
Sound Shore Management
Greenwich,
Connecticut
|
-$132M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$114M |
ALXN Hedge Fund Activity: Q4 2019 in Review
667 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2019, worth a combined $22B — up 9.1% from $20.1B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new ALXN positions and 66 closed out — a net gain of 35 holders — while 248 added to existing stakes and 237 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $103M. The largest seller was Fidelity Investments, cutting an estimated $524M.
- 667 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2019, up from 646 in Q3 2019.
- Funds reported $22B of Alexion Pharmaceuticals stock for Q4 2019, up 9.1% quarter-over-quarter.
- 101 funds opened new Alexion Pharmaceuticals positions in Q4 2019 and 66 closed out, a net change of +35 holders.
- The largest Alexion Pharmaceuticals buyer in Q4 2019 was AQR Capital Management, an estimated $103M added.
- The largest Alexion Pharmaceuticals seller in Q4 2019 was Fidelity Investments, an estimated $524M sold.
Based on aggregated 13F filings for Q4 2019.